---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-158461"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-06-11T23:59:59+00:00"
generated_at: "2026-06-01T05:03:36.559415+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Atara shareholders approve reverse stock split (1:4–1:30) and 2024 Equity Incentive Plan

## Summary
- Reverse stock split approved at board's discretion (ratio 1-for-4 to 1-for-30), board may abandon.
- 2024 Equity Incentive Plan approved: 53.96M for, 17.0M against, 24.84M broker non-votes.
- Automatic annual increase to 2024 Equity Incentive Plan rejected: 26.63M for, 44.29M against.
- Ratified Deloitte & Touche as auditors for FY2024: 89.69M for, 6.08M against.
- Two directors elected: William K. Heiden and Ameet Mallik, each with >64M votes for.

## SEC filing metadata
- accession: 0001193125-24-158461
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-06-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/0001193125-24-158461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000119312524158461/d741804d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-158461
- JSON: https://secwatch.observer/filing/0001193125-24-158461.json
- Plain text: https://secwatch.observer/filing/0001193125-24-158461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.